The L16HTHOUSE Study

L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children and adolescents with 16p11.2 deletion syndrome.

The L16HTHOUSE Study is now underway to evaluate the safety, tolerability, and effectiveness of a new medication, monitoring the results in helping with the developmental impairments in children and adolescents with the 16p11.2 deletion.

Redenlab is partnering with the Simon’s Foundation for this important trial in children and adolescents with the 16p11.2 deletion across sites in Eastern, Western and Southern USA.

To find out more about the study, click here.

Related Post

  • Posted on 30 May, 2024
    Join Redenlab at the upcoming Huntington’s Disease Society of America (HDSA) National Convention, starting on the 30th of May 2024...
    • Posted on 31 March, 2024
      Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
      • Posted on 25 January, 2024
        MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...